MiNK Therapeutics to Showcase AgenT-797 Immune Modulation in Cancer and ARDS at ASGCT
MiNK Therapeutics will present new data on AgenT-797 at the ASGCT Annual Meeting in Boston May 11-15, 2026, showcasing adaptive immune modulation in cancer and ARDS. An abstract on AgenT-797 highlights context-dependent activity of the off-the-shelf iNKT therapy in development for solid tumors and severe pulmonary inflammation.
1. ASGCT Presentation Details
MiNK Therapeutics will present an abstract titled "AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS" at the ASGCT Annual Meeting in Boston from May 11 to 15, 2026. The poster will detail context-dependent immune modulation demonstrated by the off-the-shelf iNKT cell therapy in cancer and acute respiratory distress syndrome.
2. AgenT-797 Clinical Development
AgenT-797 is an off-the-shelf allogeneic iNKT cell therapy designed to restore immune balance across cancer, graft-versus-host disease and severe pulmonary inflammation. Its dual NK-cell cytotoxicity and T-cell antigen recognition mechanism is in clinical development for solid tumors and pulmonary immune failure, with manufacturing based on a scalable cryopreserved process.